3 Bay Area companies ramp up in quests for one-shot-and-done gene therapies

As BioMarin Pharmaceutical Inc. eyes a groundbreaking approval this summer of a one-shot-and-done treatment for hemophilia A patients, it and two other Bay Area gene therapy companies made big steps Monday. BioMarin (NASDAQ: BMRN) of San Rafael paired with one-year-old Swiss company DiNAQOR AG to develop gene therapies to treat rare genetic heart diseases, and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) of Novato said the Food and Drug Administration granted "fast track" designation for a treatment?

Click to view original post